Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

View Full Paper
Ask AI
Bookmark
Share

Authors

JXJian XuWFWeijun FuYMYueying Mao

Discussion

Loading...

Member takes

Overview

Phase 2 trial found daratumumab and carfilzomib improved outcomes in ultra high-risk multiple myeloma patients, suggesting enhanced therapy benefits.

Key Points

  • The study aims to evaluate the efficacy and safety of daratumumab plus carfilzomib in ultra high-risk multiple myeloma with stem cell transplantation.
  • Multicenter phase 2 trial
  • Transplant-eligible NDMM patients aged 18-70
  • Induction with Dara-KRd-PACE followed by ASCT
  • Assessment of ORR and safety among 22 patients
  • Initial ORR was 100% after 1 induction cycle
  • 86.4% achieved ≥VGPR after 1 cycle
  • 71.4% reached sCR post-ASCT
  • Manageable grade 3/4 hematologic toxicities reported

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d153https://doi.org/10.1182/blood-2025-5828
View Full Paper
Ask AI
Bookmark
Share